

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt about the contents of this document or the action you should take, you should immediately consult your stockbroker, bank manager, solicitor, accountant, or other independent financial adviser duly authorised under the Financial Services and Markets Act 2000, if you are resident in the United Kingdom, or if not, another appropriately authorised independent adviser.

If you have sold or otherwise transferred all of your holdings of ordinary shares of £0.01 (1 pence) each (the “**Ordinary Shares**”) in the capital of Hemogenyx Pharmaceuticals plc (“**Hemogenyx Pharmaceuticals**” or the “**Company**”), you should immediately forward this document together with the enclosed documents as soon as possible to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. If you have sold or otherwise transferred some of your Ordinary Shares, you should contact the bank, stockbroker or other agent through whom the sale or transfer was effected.

The Company’s registered office is 6 Heddton Street, London, United Kingdom, W1B 4BT. Tel: +44 1727 627627. The Company is incorporated and registered in England and Wales under the Companies Act 2006 with company number 08401609.



HEMOGENYX PHARMACEUTICALS PLC

Notice of Annual General Meeting

To be held at One Heddton Street, Regent Street, London W1B 4BD on 30 June 2026 at 2 p.m. BST

This document should be read as a whole. Your attention is drawn to the letter from the Chairman of the Company which is set out in this document and which recommends that you vote in favour of the ordinary resolutions and special resolutions (the “Resolutions”) to be proposed at the Annual General Meeting (“AGM”).

Notice of the AGM of the Company, to be held at the offices of One Heddton Street, Regent Street, London W1B 4BD on 30 June 2026 at 2 p.m. BST, is set out at the end of this document.

Action to be taken by shareholders of the Company (“Shareholders”) in respect of the AGM is set out on page 3 of this document. Shareholders are asked to complete and return the enclosed Form of Proxy in accordance with the instructions printed thereon as soon as possible, but in any event so as to be received by Computershare Investor Services PLC (“Computershare”) at The Pavilions, Bridgwater Road, Bristol, BS13 8AE or by scanning a signed copy and emailing this to ExternalProxyQueries@computershare.co.uk not later than 2 p.m. BST on 26 June 2026, being 48 business hours before the AGM (or in the case of any adjournment, not later than 48 hours before the time fixed for the adjourned meeting (excluding any part of such 48 hour period falling on a non-working day)). Shareholders who hold Ordinary Shares in CREST may also appoint a proxy using CREST by following the instructions set out in the Form of Proxy and this document.

The completion and return of the Form of Proxy (by post or email, or transmission of a proxy appointment through CREST or by any other procedure described in this document) will not prevent you from attending and voting at the AGM, if you are entitled to and wish to do so. If you have any questions about this document or the AGM or are in any doubt as to how to complete the Form of Proxy or to submit your proxy electronically, please call Computershare between 8.30 a.m. and 5.30 p.m. Monday to Friday (except UK public holidays) on +44 (0)330 303

1185. Calls from outside the UK will be charged at the applicable international rate. Different charges may apply to calls from mobile telephones. Please note that calls may be monitored or recorded and Computershare cannot give any financial, legal or tax advice. A copy of this document will also be available on the Company's website, <https://hemogenyx.com>.

HEMOGENYX PHARMACEUTICALS PLC

Letter from the Chairman of Hemogenyx Pharmaceuticals plc
(Registered and incorporated in England and Wales with Company number 08401609)

Registered Office
6 Heddon Street
London
W1B 4BT
United Kingdom

5 June 2026

Dear Shareholder,

I am writing to give you details of the Company's 2026 AGM which will be held at 2 p.m. BST on 30 June 2026 at the offices of One Heddon Street, Regent Street, London W1B 4BD. The formal notice of AGM is set out on page 6 of this document and an explanation of the business to be considered and voted on at the AGM is set out on page 8.

How to attend the AGM

If you are coming to the AGM, please bring the Attendance Card portion of the Form of Proxy with you. It authenticates your right to attend, speak and vote at the AGM and will speed your admission. You may also find it useful to bring the Notice of AGM and the 2025 Annual Report and Accounts so that you can refer to them at the AGM.

How to vote

Your vote is important to us. The Directors have taken the decision that voting on the Resolutions at the AGM will be taken on a show of hands. The proxy results will also be displayed at the AGM.

Our registrar, Computershare Investor Services PLC, must receive your online or postal proxy appointment and voting instructions by 2 p.m. BST on 26 June 2026 at the latest to ensure that your vote is counted. Details of how to submit a proxy are set out on pages 10 and 11 of this document.

How to ask questions

Shareholders wishing to raise any questions relating to the business of the AGM may do so by submitting them to the Chair by email to headquarters@hemogenyx.com in advance of the AGM. All Shareholders or their proxies in attendance will have the opportunity to ask questions at the AGM. The Chair of the AGM will ensure that all such questions relating to the formal business of the AGM are addressed during the AGM, unless no response is required to be provided under the Companies Act 2006 or the provision of a response would, at the Chair's discretion, otherwise be undesirable in the interests of the Company or the good order of the AGM.

Business of the AGM

The business we will discuss at the AGM is made up of resolutions that are regularly brought to Shareholders. The formal notice of AGM and the Resolutions to be proposed at the AGM are set out on page 6 of this document. The following is a brief summary of the items of business:

- Resolution 1 relates to the receipt and adoption of the Company's annual accounts for the financial year ended 31 December 2025 together with the directors' reports and auditor's report (the "2025 Annual Report and Accounts") on those accounts;
- Resolution 2 relates to the approval of the Directors' Remuneration Report which is set out in the 2025 Annual Report and Accounts;
- Resolution 3 relates to the re-appointment of the auditors;
- Resolution 4 authorises the Audit Committee to agree the auditor's remuneration;
- Resolution 5 relates to the re-appointment as Director of Vladislav Sandler, as set out in Article 74.1 of the Articles of Association of the Company;

- Resolution 6 relates to the re-appointment as Director of Alexis Sandler, as set out in Article 74.1 of the Articles of Association of the Company;
- Resolution 7 relates to the re-appointment as Director of Sir Marc Feldmann. Whilst not necessary under the Company's Articles of Association, Principle 6 of the New QCA Corporate Governance Code 2023 (the "QCA Code") provides that, for companies that have adopted the QCA Code, as a matter of best practice, and not a legal requirement, all board members should submit themselves for re-election on an annual basis;
- Resolution 8 relates to the re-appointment as Director of Peter Redmond, who retires in accordance with Principle 6 of the QCA Corporate Governance Code and offers himself for re-appointment;
- Resolution 9 relates to the Directors' authority to allot shares;
- Resolution 10 relates to the disapplication of pre-emption rights; and
- Resolution 11 relates to the Directors' authority to call a general meeting (other than an annual general meeting) of the Company on a 14 clear days' notice period.

Action to be taken

Please check that you have received the following:

- a Form of Proxy for use in respect of the AGM on 30 June 2026; and
- a pre-paid envelope for use in the UK only for the return of the Form of Proxy.

If you have not received all of these documents, please contact the Shareholder Helpline operated by Computershare between 8.30 a.m. and 5.30 p.m. Monday to Friday (except UK public holidays) on +44 (0)330 303 1185. Calls from outside the UK will be charged at the applicable international rate. Different charges may apply to calls from mobile telephones. Please note that calls may be monitored or recorded, and Computershare cannot provide advice on the merits of the Resolutions or give any financial, legal or tax advice.

Shareholders are required to cast or amend proxy voting instructions in respect of the AGM not later than 48 hours before the AGM (or in the case of any adjournment, not later than 48 hours before the time fixed for the adjourned meeting (excluding any part of such 48 hour period falling on a non-working day)). Shareholders are entitled to appoint a proxy in respect of some or all of their Ordinary Shares and may also appoint more than one proxy, provided that each proxy is appointed to exercise the rights attached to a different share or shares held by such holder. Shareholders who wish to appoint more than one proxy in respect of their holding of Ordinary Shares should contact Computershare for further Forms of Proxy or photocopy the Form of Proxy as required.

Sending the Form of Proxy by post or by email

Please complete and sign the Form of Proxy in accordance with the instructions printed thereon and return the Form of Proxy to Computershare, the Company's registrar, either (i) by post to Computershare Investor Services PLC, The Pavilions, Bridgwater Road, Bristol, BS13 8AE, or (ii) by emailing a scanned copy to ExternalProxyQueries@computershare.co.uk, so as to be received as soon as possible and in any event not later than at 2 p.m. BST on 26 June 2026, being 48 hours before the AGM (or in the case of any adjournment, not later than 48 hours before the time fixed for the adjourned meeting (excluding any part of such 48 hour period falling on a non-working day)).

The completion and return of the Form of Proxy by post or email (or transmission of a proxy appointment through CREST or by any other procedure described in this document) will not prevent you from attending and voting at the AGM, if you are entitled to and wish to do so.

If the Form of Proxy is not lodged by the relevant time, it will be invalid.

Appointment of proxies through CREST

CREST members who wish to appoint a proxy or proxies by utilising the CREST electronic proxy appointment service may do so for the meeting and any adjournment(s) of it by using the procedures described in the CREST Manual (available from <https://my.euroclear.com/eui/en/reference/public/legal-information/crest-manual.html>). CREST Personal Members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf. In order for a proxy appointment made by means of CREST to be valid, the appropriate CREST message (a CREST Proxy Instruction) must be properly authenticated in accordance with Euroclear UK & International Limited's (EUI) specifications and must contain the information

required for such instructions, as described in the CREST Manual. The message must be transmitted so as to be received by Computershare (ID: 3RA50) by no later than 2 p.m. BST on 26 June 2026. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which Computershare is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST.

CREST members and, where applicable, their CREST sponsors or voting service providers should note that EUI does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time.

In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings. The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

Recommendation

The formal notice of AGM is set out on page 6 of this document and an explanation of each of the Resolutions to be considered at the AGM may be found on page 8 of this document. In particular, we draw your attention to the explanatory note for resolution 3 regarding the Company's external auditor and resolutions 9 and 10 regarding allotment of share capital and disapplication of pre-emption rights.

The Directors believe that the passing of the Resolutions is in the best interests of the Company and the Shareholders taken as a whole. The Directors unanimously recommend that Shareholders vote, or procure their vote, in favour of the Resolutions as they intend to do in respect of their own beneficial holdings of Ordinary Shares, amounting in aggregate to 315,578 Ordinary Shares representing approximately 4.64% per cent. of the voting rights of the current issued Ordinary Share capital of the Company.

Thank you for your ongoing support of the Company.

Yours faithfully

Professor Sir Marc Feldmann
Chairman

HEMOGENYX PHARMACEUTICALS PLC

(the “Company”)

(Registered and incorporated in England and Wales with Company number 08401609)

NOTICE IS HEREBY GIVEN that the Annual General Meeting (the “AGM”) of the Company will be held at the offices of One Heddon Street, Regent Street, London W1B 4BD on 30 June 2026 at 2 p.m. BST to consider and, if thought fit, pass the following resolutions. Resolutions 1 to 9 will be proposed as ordinary resolutions and resolutions 10 and 11 will be proposed as special resolutions.

Ordinary resolutions

Annual Report and Accounts

1. To receive and adopt the Company’s annual accounts for the financial year ended 31 December 2025 together with the directors’ reports and auditor’s report on those accounts (the “2025 Annual Report and Accounts”).

Directors’ Remuneration Report

2. To approve the Directors’ Remuneration Report (other than the Remuneration Policy) as set out in the 2025 Annual Report and Accounts, for the financial year ended 31 December 2025.

External auditor’s reappointment and remuneration

3. To reappoint PKF Littlejohn LLP as the Company’s auditor until the conclusion of the next annual general meeting of the Company.
4. To authorise the Audit Committee to determine the level of the auditor’s remuneration.

Re-appointment of Directors

5. To re-appoint as Director Vladislav Sandler, who retires by rotation under Article 74.1 of the Articles of Association of the Company and, being eligible, offers himself for re-election.
6. To re-appoint as Director Alexis Sandler, who retires by rotation under Article 74.1 of the Articles of Association of the Company and, being eligible, offers herself for re-election.
7. To re-appoint as Director Sir Marc Feldmann, who offers himself for re-election in accordance with Principle 6 of the QCA Corporate Governance Code.
8. To re-appoint as Director Peter Redmond, who offers himself for re-election in accordance with Principle 6 of the QCA Corporate Governance Code.

Directors’ authority to allot shares

9. THAT, in accordance with section 551 of the Companies Act 2006 (“CA 2006”), the Directors be generally and unconditionally authorised to allot shares in the Company and to grant rights to subscribe for, or to convert any security into, shares in the Company (the “Rights”) up to an aggregate nominal amount of £33,999.81 (representing approximately 50% of the nominal value of the issued ordinary share capital of the Company) provided that this authority shall, unless renewed, varied or revoked by the Company, expire on the commencement of the next Annual General Meeting of the Company or 30 September 2027, whichever is earlier to occur, save that the Company may, before such expiry, make offer(s) or enter agreement(s) which would or might require shares to be allotted or Rights to be granted after such expiry and the Directors may allot shares or grant Rights in pursuance of such offers or agreements notwithstanding that the authority conferred by this resolution has expired; and all unexercised authorities previously granted to the Directors to allot shares and grant Rights be and are hereby revoked.

Special resolutions

Disapplication of pre-emption rights

10. THAT, conditional on the passing of Resolution 9 above, and in accordance with section 570 of the CA 2006, the Directors be generally empowered to allot equity securities (as defined in section 560 of the CA 2006) for cash pursuant to the authority conferred by Resolution 9 or by way of a sale of treasury shares, as if section 561(1) of the CA 2006 did not apply to any such allotment, provided that this power shall be limited to:

(a) the allotment of equity securities in connection with an offer of equity securities to the holders of ordinary shares in proportion (as nearly as may be practicable) to their respective holdings; and to holders of other equity securities as required by the rights of those securities or as the Directors otherwise consider necessary, but subject to such exclusions or arrangements as the Directors may deem necessary or expedient in relation to the treasury shares, fractional entitlements, record dates, arising out of any legal or practical problems under the laws of any overseas territory or the requirements of any regulatory body or stock exchange; and

(b) the allotment of equity securities (otherwise than pursuant to sub paragraph (a) above) up to an aggregate nominal amount of £33,999.81 (representing approximately 50% of the nominal value of the issued ordinary share capital of the Company); and provided that this power shall expire on the commencement of the next Annual General Meeting of the Company or 30 September 2027, whichever is earlier to occur (unless renewed, varied or revoked by the Company prior to or on that date) save that the Company may, before such expiry, make offer(s) or agreement(s) which would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities in pursuance of any such offers or agreements notwithstanding that the power conferred by this resolution has expired.

Notice of meetings other than AGMs

11. To authorise the Directors to call a general meeting of the Company, other than an annual general meeting, on not less than 14 clear days' notice during the period from the date of the passing of this resolution 11 until the conclusion of the next Annual General Meeting of the Company.

BY ORDER OF THE BOARD
Westend Corporate LLP
Company Secretary
5 June 2026

6 Heddon Street,
London, United Kingdom,
W1B 4BT

EXPLANATORY NOTES TO THE RESOLUTIONS

References to page numbers in the 2025 Annual Report and Accounts for the financial year ended 31 December 2025 are to the signed version of the report published on the Company's website and uploaded to the National Storage Mechanism on 5 May 2026. These page numbers may differ from the printed version of the Annual Report accompanying this notice.

RESOLUTION 1 – ANNUAL REPORT AND ACCOUNTS

The Directors are required to present to the AGM the 2025 Annual Report and Accounts for the financial year ended 31 December 2025.

RESOLUTION 2 – DIRECTORS' REMUNERATION REPORT

In accordance with section 439 of the Companies Act 2026, Shareholders are requested to approve the Directors' Remuneration Report. The Directors' Remuneration Report is set out on pages 33 to 38 of the 2025 Annual Report and Accounts. The vote is advisory only and does not affect the actual remuneration paid to an individual director.

RESOLUTIONS 3 AND 4 – EXTERNAL AUDITOR'S REAPPOINTMENT AND REMUNERATION

The auditor is appointed at every general meeting at which accounts are presented to Shareholders. The current appointment of PKF Littlejohn LLP as the Company's auditor will end at the conclusion of the AGM and it has advised its willingness to stand for reappointment. In accordance with the provisions of the Code of Corporate Governance published by the Financial Reporting Council in 2018, it is recommended best practice for the Audit Committee to be authorised to agree how much the auditor should be paid and Resolution 4 grants this authority to the Audit Committee.

RESOLUTION 5 – RE-ELECTION OF A DIRECTOR

In accordance with Article 74.1 of the Company's Articles of Association, each Director shall retire from office at the third annual general meeting of the Company and may offer himself for reappointment by the members. Vladislav Sandler is therefore subject to re-appointment.

RESOLUTION 6 – RE-ELECTION OF A DIRECTOR

In accordance with Article 74.1 of the Company's Articles of Association, each Director shall retire from office at the third annual general meeting of the Company and may offer herself for reappointment by the members. Alexis Sandler is therefore subject to re-appointment.

RESOLUTION 7 – RE-ELECTION OF A DIRECTOR

Whilst not necessary under the Company's Articles of Association, Principle 6 of the QCA Corporate Governance Code 2023 (the "QCA Code") provides that, for companies that have adopted the QCA Code, as a matter of best practice, and not a legal requirement, all board members should submit themselves for re-election on an annual basis. Accordingly, Sir Marc Feldmann will retire from office and offers himself for re-appointment.

RESOLUTION 8 – RE-ELECTION OF A DIRECTOR

Whilst not necessary under the Company's Articles of Association, Principle 6 of the QCA Code provides that, for companies that have adopted the QCA Code, as a matter of best practice, and not a legal requirement, all board members should submit themselves for re-election on an annual basis. Accordingly, Peter Redmond will retire from office and offers himself for re-appointment.

RESOLUTION 9 – ALLOTMENT OF SHARE CAPITAL

Resolution 9 grants the Directors general authority to allot ordinary shares in the capital of the Company or to grant rights to subscribe for, or to convert any security into, such shares in the Company up to an aggregate nominal amount of £33,999.81, representing approximately 50% of the Company's current issued share capital.

The Company is currently in the clinical trial stage for its lead product candidate HG-CT-1. Clinical development activities are inherently capital-intensive and lead to a significantly increased expenditure rate.

In order to maintain strategic and operational flexibility, the Company must ensure it has access to timely and efficient financing options, including equity financing. Shareholders will be aware in general of the much increased level of costs incurred, arising from the preparation and conduct of clinical trials of HG-CT-1 and the fact that this will continue for a considerable amount of time.

While the Directors will continue to seek non-diluting funds, granting this authority enables the Company to respond swiftly to market opportunities and potential funding needs without delay or the expense of convening additional shareholder meetings, with the further delay and cost of doing so. This authority is therefore considered prudent and in the best interests of shareholders given the Company's stage of development and evolving capital requirements.

Resolutions 1 to 9 will be proposed as ordinary resolutions and require that more than half of the votes cast must be in favour of a resolution for it to be passed.

RESOLUTION 10 – DISAPPLICATION OF PRE-EMPTION RIGHTS

Section 561(1) of the Companies Act 2006 requires that on an allotment of new shares for cash, such shares must first be offered to existing Shareholders in proportion to the number of shares that they each hold at that time. The Directors believe that there may be circumstances when it is in the best interests of the Company to allot new ordinary shares either on an entirely non-pre-emptive basis or in a way that departs from the statutory requirements set out in the Companies Act 2006. Resolution 10 grants the Directors general authority to allot shares or grant rights over shares for cash and otherwise than to existing shareholders pro rata to their holdings. The authority will be limited to shares of a maximum aggregate nominal value of £33,999.81, being 50% of the issued ordinary share capital. This authority, if given, will expire (unless previously revoked or varied by the Company in general meeting) at the earlier of the conclusion of the next annual general meeting in 2027 or on the date which is 15 months after the relevant resolution is passed.

The particular reasons for the disapplication sought in this resolution are the same as those given in respect of Resolution 9 above.

RESOLUTION 11– NOTICE OF MEETINGS OTHER THAN ANNUAL GENERAL MEETINGS

The Directors wish to obtain the flexibility and benefit from the ability to call general meetings on 14 clear days' notice and this Resolution, which is proposed as a special resolution, seeks authority from Shareholders for this flexibility. Such approval will not affect annual general meetings, which will continue to be held on at least 21 clear days' notice. In the event that this authority is to be exercised, the Directors will ensure that it is not used as a matter of routine, but only where the flexibility is merited by the business of the meeting and is thought to be to the advantage of Shareholders as a whole. The Company intends to meet the requirements for a means of electronic voting to be made available to all Shareholders before calling a meeting on 14 clear days' notice. The approval will be effective until the Company's next annual general meeting, when it is intended that a similar resolution will be proposed.

Resolutions 10 and 11 will be proposed as special resolutions and require that at least three quarters of the votes cast must be in favour of a resolution for it to be passed.

Notice of AGM Notes:

Shareholders are strongly encouraged to appoint “the Chair of the AGM” as their proxy.

Entitlement to Attend and Vote

1. To be entitled to attend and vote at the AGM (and for the purposes of the determination by the Company of the votes that may be cast in accordance with Section 360B(2) of the Act and Regulation 41 of the Uncertified Securities Regulations 2001), only those members registered in the Company’s register of members at 2 p.m. BST on 26 June 2026 (or, if the meeting is adjourned, 2 days before the adjourned meeting) shall be entitled to attend and vote at the meeting. Changes to the register of members of the Company after the relevant deadline shall be disregarded in determining the rights of any person to attend and vote at the AGM.

Appointment of Proxies

2. If you are a member of the Company at the time set out in note 1 above, you are entitled to appoint a proxy to exercise all or any of your rights to attend, speak and vote at the meeting. You can appoint a proxy only using the procedures set out in these notes and the notes to the proxy form.
3. Shareholders are strongly encouraged to submit proxy appointments and instructions for the AGM as soon as possible, using any of the methods (by post, by email, or through CREST) set out below.
4. A Shareholder entitled to attend and vote at the AGM may appoint one or more proxies to exercise all or any of the Shareholder’s rights to attend, submit written questions and, on a poll, to vote instead of him or her. A proxy need not be a member of the Company but must attend the AGM for the Shareholder’s vote to be counted. If a Shareholder appoints more than one proxy to attend the AGM, each proxy must be appointed to exercise the rights attached to a different share or shares held by the Shareholder. If a Shareholder wishes to appoint more than one proxy, they should contact Computershare for further forms of proxy or photocopy the form of proxy as required.
5. A vote withheld is not a vote in law, which means that the vote will not be counted in the calculation of votes for or against the Resolution. If no voting indication is given, your proxy will vote or abstain from voting at his or her discretion. Your proxy will vote (or abstain from voting) as he or she thinks fit in relation to any other matter which is put before the meeting.
6. The completion and return of the Form of Proxy by post or email (or transmission of a proxy appointment through CREST or by any other procedure described below) will not prevent you from attending and voting at the AGM, if you are entitled to and wish to do so.

Appointment of Proxy Using Hard Copy Proxy Form or by Email

7. A Form of Proxy for use at the AGM has been provided with this notice. Instructions for its use are set out on the Form of Proxy. It is requested that the Form of Proxy (together with any power of attorney or other authority, if any, under which it is signed, or a duly certified copy thereof) be returned to the Company’s Registrar, Computershare, either (i) by post to Computershare Investor Services PLC, The Pavilions, Bridgwater Road, Bristol, BS13 8AE, or (ii) by emailing a scanned copy to ExternalProxyQueries@computershare.co.uk, so as to be received as soon as possible and in any event not later than 2 p.m. BST on 26 June 2026 (or, in the case of an adjournment of the AGM, 48 hours before the time appointed for the adjourned meeting (excluding any part of such 48 hour period falling on a non-working day)).
8. If the Form of Proxy for the AGM is not lodged by the relevant time, it will be invalid.

Appointment of Proxies Through CREST

9. CREST members who wish to appoint a proxy or proxies by utilising the CREST electronic proxy appointment service may do so for the meeting and any adjournment(s) of it by using the procedures described in the CREST Manual (available from <https://my.euroclear.com/eui/en/reference/public/legal-information/crest-manual.html>). CREST Personal Members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf. In order for a proxy appointment made by means of CREST to be valid, the appropriate CREST message (a CREST Proxy Instruction) must be properly authenticated in accordance with Euroclear UK &

International Limited's (EUI) specifications and must contain the information required for such instructions, as described in the CREST Manual. The message must be transmitted so as to be received by the issuer's agent (ID: 3RA50) by no later than 2 p.m. BST on 26 June 2026. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST.

10. CREST members and, where applicable, their CREST sponsors or voting service providers should note that EUI does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time.
11. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings. The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

Appointment of Proxy by Joint Members

12. In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding, the first-named being the most senior.

Changing Proxy Instructions

13. To change your proxy instructions simply submit a new proxy appointment using the methods set out above. Note that the cut-off times for receipt of proxy appointments (see above) also apply in relation to amended instructions; any amended proxy appointment received after the relevant cut-off time will be disregarded. Where you have appointed a proxy using a hard-copy proxy form and would like to change the instructions using another hard-copy proxy form, please contact Computershare as per the communication methods shown in note 7 above. If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence. If the Company is unable to determine which Form of Proxy was last validly received, none of them shall be treated as valid in respect of the same.

Termination of Proxy Appointments

14. In order to revoke a proxy instruction, you will need to inform the Company by sending a signed hard copy notice clearly stating your intention to revoke your proxy appointment to Computershare, at the address shown in note 7. In the case of a member which is a company, the revocation notice must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which the revocation notice is signed, or a duly certified copy of such power or authority, must be included with the revocation notice. The revocation notice must be received by Computershare no later than 48 hours before the AGM. If you attempt to revoke your proxy appointment but the revocation is received after the time specified then, subject to the paragraph directly below, your proxy appointment will remain valid. The completion and return of the Form of Proxy by post or email (or transmission of a proxy appointment through CREST or by any other procedure described herein) will not prevent you from remotely following and submitting written questions to the AGM, in each case via the Virtual Meeting Platform, if you are entitled to and wish to do so.

Corporate Representatives

15. A corporation which is a member can appoint one or more corporate representatives who may exercise, on its behalf, all its powers as a member provided that no more than one corporate representative exercises powers over the same share.

Votes to be Taken on a Show of Hands and Final Proxy Results

16. At the AGM voting on the Resolutions will be taken on a show of hands. The final proxy results will be available at the AGM, announced through a regulatory information service and published on the Company's website as soon as reasonably practicable following the conclusion of the AGM.

Nominated Persons

17. If you are a person who has been nominated under section 146 of the Companies Act 2006 to enjoy information rights ("Nominated Person"), you may have a right under an agreement between you and the Shareholder of the Company who has nominated you to have information rights ("Relevant Shareholder") to be appointed or to have someone else appointed as a proxy for the AGM. If you either do not have such a right or if you have such a right but do not wish to exercise it, you may have a right under an agreement between you and the Relevant Shareholder to give instructions to the Relevant Shareholder as to the exercise of voting rights. Your main point of contact in terms of your investment in the Company remains the Relevant Shareholder (or, perhaps, your custodian or broker) and you should continue to contact them (and not the Company) regarding any changes or queries relating to your personal details and your interest in the Company (including any administrative matters). The only exception to this is where the Company expressly requests a response from you.

Website Providing Information Regarding the AGM

18. Information regarding the AGM, including information required by section 311A of the Companies Act 2006, and a copy of this notice of AGM may be found on our website at <https://hemogenyx.com>.

Issued Shares and Total Voting Rights

19. As at close of business on the day immediately prior to the date of posting of this notice of AGM, the Company's issued share capital comprised 6,799,961 ordinary shares and 1,401,815,988 deferred shares. Each ordinary share carries the right to one vote at a general meeting of the Company and deferred shares do not carry the right to vote. Therefore, the total number of voting rights in the Company as at close of business on the day immediately prior to the date of posting of this notice of AGM is 6,799,961. On a vote by poll, each shareholder has one vote for every voting share held.

Questions at the AGM

20. Any member attending the AGM has the right to ask questions. The Company must answer any question you ask relating to the business being dealt with at the meeting unless (i) answering the question would interfere unduly with the preparation for the meeting or involve the disclosure of confidential information, (ii) the answer has already been given on a website in the form of any answer to a question; or (iii) it is undesirable in the interests of the Company or the good order of the meeting that the question be answered.

Electronic Address

21. You may not use any electronic address (within the meaning of Section 333(4) of the Companies Act 2006) provided in this notice of AGM (or in any related documents including the form of proxy) to communicate with the Company for any purposes other than those expressly stated.

Website Publication of Audit Concerns

22. Under section 527 of the Companies Act 2006, members meeting the threshold requirements set out in that section have the right to require the Company to publish on a website a statement setting out any matter relating to: (i) the audit of the Company's accounts (including the Auditors' report and the conduct of the audit) that are to be laid before the AGM; or (ii) any circumstance connected with an auditor of the Company ceasing to hold office since the previous meeting at which annual accounts and reports were laid in accordance with section 437 of the Companies Act 2006. The Company may not require the members requesting such website publication to pay its expenses in complying with section 527 or 528

of the Companies Act 2006, and it must forward the statement to the Company's Auditors not later than the time when it makes the statement available on the website. The business which may be dealt with at the AGM includes any statement that the Company has been required under section 527 of the Companies Act 2006 to publish on its website.

Documents Available for Inspection

23. Copies of the service contracts of the Executive Directors and the Non-Executive Directors' terms of appointment are available for inspection at the registered office of the Company during normal business hours from the date of this notice of AGM and at the place of the meeting for a period from 15 minutes immediately before the AGM until its conclusion. Please email headquarters@hemogenyx.com during normal business hours on any weekday (excluding public holidays) to arrange an appointment.

